Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Oxidative pentose phosphate pathway inhibition is a key determinant of antimalarial induced cancer cell death

Oncogene volume 35, pages 2913–2922 (2016)Cite this article

Subjects

Abstract

Despite immense interest in using antimalarials as autophagy inhibitors to treat cancer, it remains unclear whether these agents act predominantly via autophagy inhibition or whether other pathways direct their anti-cancer properties. By comparing the treatment effects of the antimalarials chloroquine (CQ) and quinacrine (Q) on KRAS mutant lung cancer cells, we demonstrate that inhibition of the oxidative arm of the pentose phosphate pathway (oxPPP) is required for antimalarial induced apoptosis. Despite inhibiting autophagy, neither CQ treatment nor RNAi against autophagy regulators (ATGs) promote cell death. In contrast, Q triggers high levels of apoptosis, both in vitro and in vivo, and this phenotype requires both autophagy inhibition and p53-dependent inhibition of the oxPPP. Simultaneous genetic targeting of the oxPPP and autophagy is sufficient to trigger apoptosis in lung cancer cells, including cells lacking p53. Thus, in addition to reduced autophagy, oxPPP inhibition serves as an important determinant of antimalarial cytotoxicity in cancer cells.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Murrow L, Debnath J . Autophagy as a stress-response and quality-control mechanism: implications for cell injury and human disease. Annu Rev Pathol 2013; 8: 105–137.

    Article  CAS  PubMed  Google Scholar 

  2. Kimmelman AC . The dynamic nature of autophagy in cancer. Genes Dev 2011; 25: 1999–2010.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Amaravadi RK, Lippincott-Schwartz J, Yin XM, Weiss WA, Takebe N, Timmer W et al. Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res 2011; 17: 654–666.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Barnard RA, Wittenburg LA, Amaravadi RK, Gustafson DL, Thorburn A, Thamm DH . Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma. Autophagy 2014; 10: 1415–1425.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Mahalingam D, Mita M, Sarantopoulos J, Wood L, Amaravadi RK, Davis LE et al. Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors. Autophagy 2014; 10: 1403–1414.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Rangwala R, Chang YC, Hu J, Algazy KM, Evans TL, Fecher LA et al. Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy 2014; 10: 1391–1402.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Rangwala R, Leone R, Chang YC, Fecher LA, Schuchter LM, Kramer A et al. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy 2014; 10: 1369–1379.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Rosenfeld MR, Ye X, Supko JG, Desideri S, Grossman SA, Brem S et al. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy 2014; 10: 1359–1368.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Vogl DT, Stadtmauer EA, Tan KS, Heitjan DF, Davis LE, Pontiggia L et al. Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma. Autophagy 2014; 10: 1380–1390.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Wolpin BM, Rubinson DA, Wang X, Chan JA, Cleary JM, Enzinger PC et al. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Oncologist 2014; 19: 637–638.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Maycotte P, Aryal S, Cummings CT, Thorburn J, Morgan MJ, Thorburn A . Chloroquine sensitizes breast cancer cells to chemotherapy independent of autophagy. Autophagy 2012; 8: 200–212.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Maes H, Kuchnio A, Peric A, Moens S, Nys K, De Bock K et al. Tumor vessel normalization by chloroquine independent of autophagy. Cancer Cell 2014; 26: 190–206.

    Article  CAS  PubMed  Google Scholar 

  13. Gallant JN, Allen JE, Smith CD, Dicker DT, Wang W, Dolloff NG et al. Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. Cancer Biol Ther 2011; 12: 239–251.

    Article  CAS  PubMed  Google Scholar 

  14. Gurova KV, Hill JE, Guo C, Prokvolit A, Burdelya LG, Samoylova E et al. Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci USA 2005; 102: 17448–17453.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Ehsanian R, Van Waes C, Feller SM . Beyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers. Cell Commun Signal 2011; 9: 13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Gupta A, Roy S, Lazar AJ, Wang WL, McAuliffe JC, Reynoso D et al. Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST). Proc Natl Acad Sci USA 2010; 107: 14333–14338.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Geng Y, Kohli L, Klocke BJ, Roth KA . Chloroquine-induced autophagic vacuole accumulation and cell death in glioma cells is p53 independent. Neuro Oncol 2010; 12: 473–481.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Guo JY, Chen HY, Mathew R, Fan J, Strohecker AM, Karsli-Uzunbas G et al. Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev 2011; 25: 460–470.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Guo JY, Karsli-Uzunbas G, Mathew R, Aisner SC, Kamphorst JJ, Strohecker AM et al. Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev 2013; 27: 1447–1461.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Lock R, Roy S, Kenific CM, Su JS, Salas E, Ronen SM et al. Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation. Mol Biol Cell 2011; 22: 165–178.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Yang S, Wang X, Contino G, Liesa M, Sahin E, Ying H et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev 2011; 25: 717–729.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Lock R, Kenific CM, Leidal AM, Salas E, Debnath J . Autophagy-dependent production of secreted factors facilitates oncogenic RAS-driven invasion. Cancer Discov 2014; 4: 466–479.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012; 8: 445–544.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Buchakjian MR, Kornbluth S . The engine driving the ship: metabolic steering of cell proliferation and death. Nat Rev Mol Cell Biol 2010; 11: 715–727.

    Article  CAS  PubMed  Google Scholar 

  25. Schafer ZT, Grassian AR, Song L, Jiang Z, Gerhart-Hines Z, Irie HY et al. Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature 2009; 461: 109–113.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Bakkenist CJ, Kastan MB . DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003; 421: 499–506.

    Article  CAS  PubMed  Google Scholar 

  27. Maclean KH, Dorsey FC, Cleveland JL, Kastan MB . Targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. J Clin Invest 2008; 118: 79–88.

    Article  CAS  PubMed  Google Scholar 

  28. Vousden KH, Ryan KM . p53 and metabolism. Nat Rev Cancer 2009; 9: 691–700.

    Article  CAS  PubMed  Google Scholar 

  29. Jiang P, Du W, Wang X, Mancuso A, Gao X, Wu M et al. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat Cell Biol 2011; 13: 310–316.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Maycotte P, Gearheart CM, Barnard R, Aryal S, Mulcahy Levy JM, Fosmire SP et al. STAT3-mediated autophagy dependence identifies subtypes of breast cancer where autophagy inhibition can be efficacious. Cancer Res 2014; 74: 2579–2590.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Karsli-Uzunbas G, Guo JY, Price S, Teng X, Laddha SV, Khor S et al. Autophagy is required for glucose homeostasis and lung tumor maintenance. Cancer Discov 2014; 4: 914–927.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Rosenfeldt MT, O'Prey J, Morton JP, Nixon C, MacKay G, Mrowinska A et al. p53 status determines the role of autophagy in pancreatic tumour development. Nature 2013; 504: 296–300.

    Article  CAS  PubMed  Google Scholar 

  33. Yang A, Rajeshkumar NV, Wang X, Yabuuchi S, Alexander BM, Chu GC et al. Autophagy is critical for pancreatic tumor growth and progression in tumors with p53 alterations. Cancer Discov 2014; 4: 905–913.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. McAfee Q, Zhang Z, Samanta A, Levi SM, Ma XH, Piao S et al. Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency. Proc Natl Acad Sci USA 2012; 109: 8253–8258.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Fung C, Lock R, Gao S, Salas E, Debnath J . Induction of autophagy during extracellular matrix detachment promotes cell survival. Mol Biol Cell 2008; 19: 797–806.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Grant support to JD includes the NIH (R01CA126792 and R01CA188404), California Tobacco Related Diseases Research Program (18XT-0106) and Samuel Waxman Cancer Research Foundation.

Author contributions

JD and BR conceived the study. ES, SR, TM and JD designed the experiments. ES, SR and TM performed the experiments. ES, SR, TM and JD analyzed the data. JD supervised the study and wrote the paper with input from the other authors.

Author information

Authors and Affiliations

  1. Department of Pathology and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA

    E Salas, S Roy, T Marsh & J Debnath

  2. Departments of Anatomic Pathology and Molecular Genetics, Cleveland Clinic, Cleveland, OH, USA

    B Rubin

Authors
  1. E Salas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Roy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Marsh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B Rubin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Debnath
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J Debnath.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Oncogene website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Salas, E., Roy, S., Marsh, T. et al. Oxidative pentose phosphate pathway inhibition is a key determinant of antimalarial induced cancer cell death. Oncogene 35, 2913–2922 (2016). https://doi.org/10.1038/onc.2015.348

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2015.348

This article is cited by

Search

Advanced search

Quick links